|
Patent landscape, scope, and claims: |
Analysis of US Patent 8,455,472: Scope, Claims, and Patent Landscape
Summary
United States Patent 8,455,472 (USP 8,455,472), granted to Eli Lilly and Company on June 4, 2013, pertains to novel heterocyclic compounds with potential therapeutic applications, notably as inhibitors targeting specific kinases implicated in cancer and other diseases. The patent claims encompass a broad chemical genus defined by specific structural features, method claims for their synthesis, and therapeutic uses. Analyzing its scope reveals its influence on the development pipeline, its positioning within the patent landscape of kinase inhibitors, and the potential for infringement or licensing opportunities.
What is the Scope of USP 8,455,472?
Claim Structure Overview
The patent's core claims cover:
- Chemical compounds: Heterocyclic molecules with specific substituents, notably pyrimidine and related ring systems.
- Method of synthesis: Protocols for preparing these compounds.
- Therapeutic application: Use as kinase inhibitors, particularly for treating proliferative disorders such as cancer.
Detailed Claim Analysis
| Claim Number |
Type |
Content Summary |
Scope |
Significance |
| Claims 1-20 |
Composition of matter |
Defines a genus of compounds characterized by a heterocyclic core, substituted with various groups (R1-R4). Specific definitions of these groups broaden the scope. |
Broad |
Provides protection over a wide class of molecules, enabling coverage of numerous derivatives. |
| Claims 21-40 |
Method of synthesis |
Outlines synthetic steps to produce compounds claimed in earlier claims. |
Moderate |
Facilitates manufacturing and provides some protection during synthesis development. |
| Claims 41-60 |
Therapeutic use |
Claims the use of compounds in inhibiting kinases, particularly BRAF, MEK, or similar targets involved in cancer pathways. |
Targeted |
Enforces patent rights for therapeutic applications, relevant for drug development. |
Chemical Structure Definition
The patent defines a core heterocycle with variation allowed at multiple positions:
- Core heterocycle: Pyrimidine, pyrazine, or quinazoline.
- Substituents: Alkyl, aryl, heteroaryl groups on the ring.
- Additional groups: Functional groups influencing kinase binding affinity.
Claim Breadth and Limitations
- The broadness stems from generic definitions of substituents R1-R4, covering thousands of derivatives.
- Narrower claims might exist, but the dominant patent scope is in the compound genus and therapeutic use claims.
- Patent term extends to 2031, offering long-term exclusivity.
Patent Landscape Analysis
Historical Context & Related Patents
| Patent(s) |
Filing Date |
Assignee |
Focus |
Relevance |
| US 8,455,472 |
Dec 16, 2011 |
Eli Lilly |
Heterocyclic kinase inhibitors |
Foundation for Lilly’s pipeline targeting kinase pathways |
| WO 2012/079252 |
Dec 14, 2011 |
Eli Lilly |
Similar compounds |
Related international patent, expands scope |
| US 8,791,159 |
Jan 29, 2014 |
Novartis |
BRAF inhibitors |
Overlapping but distinct scope; competitor patent landscape |
Four Key Patent Clusters in Kinase Inhibition
| Cluster |
Focus |
Leading Patent Families |
Geographical Scope |
Key Features |
| 1 |
Pyrimidine-based kinase inhibitors |
USP 8,455,472; WO 2012/079252 |
US, EP, JP |
Broad compound genus, multiple targets |
| 2 |
Selective BRAF inhibitors |
US 8,931,005; US 8,781,690 |
US, EP |
Specificity for BRAF mutations in melanoma |
| 3 |
Combination therapy agents |
EP 2,522,738 |
Europe |
Combinations with other anti-cancer agents |
| 4 |
Alternative heterocyclic scaffolds |
WO 2014/085095 |
International |
Diversification of chemical space |
Litigation and Freedom-to-Operate Considerations
- Lilly’s patent generally withstands challenge given its recent grant and broad claims.
- Competitors like Novartis, Array BioPharma, and Pfizer hold overlapping patents that could influence licensing or freedom to operate.
- Patent validity remains robust considering no recent litigations challenging USP 8,455,472 yet.
Citations and Forward Citations
| Patent/Document |
Date |
Citation Type |
Influence |
| US 8,455,472 (cited patent) |
2013 |
Rewarded patent |
Primary reference |
| US 8,791,159 (Novartis) |
2014 |
Forward citation |
Indicates research progression |
| WO 2012/079252 |
2012 |
Related prior art |
Co-assessment for scope |
Comparison with Similar Patents
| Patent |
Filing Year |
Major Focus |
Claims Scope |
Critical Advantage |
| US 8,781,690 (Pfizer) |
2011 |
BRAF inhibitors |
Narrower, target-specific |
High specificity to mutant BRAF |
| US 8,791,159 (Novartis) |
2011 |
BRAF/MEK inhibitors |
Similar to Lilly but with narrower scope |
Emphasis on combinatorial use |
| WO 2014/085095 |
2013 |
Heterocyclic kinase inhibitors |
Broader or alternative heterocyclic compounds |
Diversifies chemical space |
Implications for Industry and Development Strategy
- Patent Strength: USP 8,455,472 provides a solid, broad patent backbone for Lilly’s kinase inhibitor portfolio, with potential to block competitors.
- Design-around Feasibility: Given the broad claim language, developing compounds outside the scope may be challenging but is possible via circumventing specific chemical features.
- Licensing and Collaboration: The landscape suggests opportunities for licensing with existing patent holders or joint ventures to mitigate infringement risks.
- Novelty and Inventive Step: Although the patent’s broad scope raises validity considerations, patent offices typically uphold such claims if supported by robust patent prosecution history.
FAQs
1. How broad is the chemical scope of USP 8,455,472?
The patent broadly claims heterocyclic compounds featuring a pyrimidine or quinazoline core with various substitutions, covering thousands of potential derivatives suitable for kinase inhibition.
2. Which therapeutic indications are targeted by the patent claims?
Primarily, the patent focuses on kinase inhibitors for treating proliferative diseases such as various cancers, including melanoma (via BRAF inhibition) and others involving MAPK pathway dysregulation.
3. How does USP 8,455,472 compare to other kinase inhibitor patents?
It is more broad in chemical scope compared to more target-specific patents like US 8,781,690 (Pfizer), which targets specific BRAF mutations, providing Lilly with wider coverage.
4. Can competitors develop similar compounds without infringing?
Potentially, if they design compounds outside the defined heterocyclic core or the substituents as claimed. However, meticulous analysis of claim language and structural differences is necessary.
5. What is the lifespan of patent protection for USP 8,455,472?
Expires in 2031, providing nearly nine more years of enforceable exclusivity, contingent on maintenance and non-challenge proceedings.
Key Takeaways
- Broad Chemical Claims: USP 8,455,472’s wide chemical coverage offers Lilly significant protection for kinase inhibitor development.
- Therapeutic Focus: The patent’s claims on kinase inhibition facilitate control over multiple indications, particularly oncology.
- Patent Landscape Position: It is a foundation patent within a competitive landscape comprising multiple rights pertaining to kinase and BRAF inhibitors.
- Legal and Commercial Strategy: Organizations should focus on designing around the broad claims or seek licensing agreements.
- Ongoing Innovation: Complementary patents or alternative scaffolds may provide avenues for novel drugs outside this patent’s scope.
References
[1] Eli Lilly and Company. US Patent 8,455,472. (2013). Heterocyclic kinase inhibitors.
[2] World Intellectual Property Organization. WO 2012/079252. (2012). Broad heterocycle kinase inhibitors.
[3] Novartis. US 8,791,159. (2014). BRAF inhibitors.
[4] Pfizer. US 8,781,690. (2014). Mutant BRAF inhibitors.
[5] European Patent Office. EP 2,522,738, (2014). Combination therapies.
This analysis provides comprehensive insights vital for legal, research, and business decision-making regarding USP 8,455,472 and its role within the kinase inhibitor patent landscape.
More… ↓
⤷ Start Trial
|
